Literature DB >> 31049320

Tumour Expression of Histone Deacetylases in Uveal Melanoma.

Louis Levinzon1, Michele Madigan1, Vuong Nguyen1, Enisa Hasic1, Max Conway1, Svetlana Cherepanoff1.   

Abstract

PURPOSE: To determine the expression of histone deacetylase enzymes in uveal melanoma tumour cells. PROCEDURES: This is an observational immunohistochemical study of 16 formalin-fixed, paraffin-embedded eyes enucleated for uveal melanoma between January 2001 and March 2002. Haematoxylin and eosin paraffin sections were reviewed for histopathological parameters according to the American Joint Committee on Cancer 7th edition. Sections were then immunohistochemically stained for histone deacetylases 1, 2, 3, 4 and 6 and sirtuin 2 using an automated Leica Bond II platform and Fast Red chromogen, then digitally scanned using Aperio software before assessment of staining.
RESULTS: Nuclear expression of histone deacetylases 1, 2, 3, 4 and 6 and of sirtuin 2 was confirmed in uveal melanoma tumour cells. In addition, the tumour cells showed cytoplasmic expression of histone deacetylases 4 and 6 and sirtuin 2. Nuclear and cytoplasmic immunostaining was also seen in intraocular tissues uninvolved by the tumour.
CONCLUSION: Uveal melanoma tumour cells express histone deacetylases 1, 2, 3, 4 and 6 and sirtuin 2, confirming potential tissue targets for histone deacetylase inhibitors.

Entities:  

Keywords:  Histone deacetylases; Immunohistochemistry; Sirtuins; Uveal melanoma

Year:  2018        PMID: 31049320      PMCID: PMC6489079          DOI: 10.1159/000490038

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  42 in total

Review 1.  Management of posterior uveal melanoma: past, present, future.

Authors:  Jerry A Shields
Journal:  Retina       Date:  2002-04       Impact factor: 4.256

2.  Cytoplasmic and nuclear interaction between Rb family proteins and PAI-2: a physiological crosstalk in human corneal and conjunctival epithelial cells.

Authors:  M Macaluso; M Montanari; C M Marshall; A J Gambone; G M Tosi; A Giordano; M Massaro-Giordano
Journal:  Cell Death Differ       Date:  2006-01-06       Impact factor: 15.828

3.  Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate.

Authors:  Muthusamy Thangaraju; Senthil K Karunakaran; Shiro Itagaki; Elangovan Gopal; Selvakumar Elangovan; Puttur D Prasad; Vadivel Ganapathy
Journal:  Cancer       Date:  2009-10-15       Impact factor: 6.860

4.  Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.

Authors:  Anupama Munshi; Toshimitsu Tanaka; Marvette L Hobbs; Susan L Tucker; Victoria M Richon; Raymond E Meyn
Journal:  Mol Cancer Ther       Date:  2006-08       Impact factor: 6.261

Review 5.  Epigenetic lesions in malignant melanoma.

Authors:  M Schwabe; M Lübbert
Journal:  Curr Pharm Biotechnol       Date:  2007-12       Impact factor: 2.837

Review 6.  Histone deacetylase inhibitors: overview and perspectives.

Authors:  Milos Dokmanovic; Cathy Clarke; Paul A Marks
Journal:  Mol Cancer Res       Date:  2007-10       Impact factor: 5.852

7.  Single-cell tumor dormancy model of uveal melanoma.

Authors:  Patrick T Logan; Bruno F Fernandes; Sebastian Di Cesare; Jean-Claude A Marshall; Shawn C Maloney; Miguel N Burnier
Journal:  Clin Exp Metastasis       Date:  2008-03-12       Impact factor: 5.150

Review 8.  HDAC expression and clinical prognosis in human malignancies.

Authors:  Wilko Weichert
Journal:  Cancer Lett       Date:  2008-12-21       Impact factor: 8.679

Review 9.  Histone deacetylases: target enzymes for cancer therapy.

Authors:  Denis Mottet; Vincent Castronovo
Journal:  Clin Exp Metastasis       Date:  2007-12-05       Impact factor: 5.150

10.  Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

Authors:  P N Munster; D Marchion; S Thomas; M Egorin; S Minton; G Springett; J-H Lee; G Simon; A Chiappori; D Sullivan; A Daud
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

View more
  9 in total

1.  HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma.

Authors:  Sathya Neelature Sriramareddy; Fernanda Faião-Flores; Michael F Emmons; Biswarup Saha; Srikumar Chellappan; Clayton Wyatt; Inna Smalley; Jonathan D Licht; Michael A Durante; J William Harbour; Keiran S M Smalley
Journal:  Cancer Gene Ther       Date:  2022-03-24       Impact factor: 5.854

2.  Current molecular and clinical insights into uveal melanoma (Review).

Authors:  Matteo Fallico; Giuseppina Raciti; Antonio Longo; Michele Reibaldi; Vincenza Bonfiglio; Andrea Russo; Rosario Caltabiano; Giuseppe Gattuso; Luca Falzone; Teresio Avitabile
Journal:  Int J Oncol       Date:  2021-03-02       Impact factor: 5.650

Review 3.  Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.

Authors:  Nuno Jorge Lamas; Arnaud Martel; Sacha Nahon-Estève; Samantha Goffinet; Adam Macocco; Corine Bertolotto; Sandra Lassalle; Paul Hofman
Journal:  Cancers (Basel)       Date:  2021-12-25       Impact factor: 6.639

4.  Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor.

Authors:  Husvinee Sundaramurthi; Sandra García-Mulero; Valentina Tonelotto; Kayleigh Slater; Simone Marcone; Josep M Piulats; Ronald William Watson; Desmond J Tobin; Lasse D Jensen; Breandán N Kennedy
Journal:  Cancers (Basel)       Date:  2022-02-03       Impact factor: 6.639

Review 5.  Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma.

Authors:  Husvinee Sundaramurthi; Zoltán Giricz; Breandán N Kennedy
Journal:  Int J Mol Sci       Date:  2022-08-19       Impact factor: 6.208

6.  Identification of 5 microRNA biomarkers associated with the prognosis of uveal melanoma.

Authors:  Yabin Sun; Xinmin Zhang; Zhongyi Cong; Siying Teng
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

7.  Inhibiting the activation of MAPK (ERK1/2) in stressed Müller cells prevents photoreceptor degeneration.

Authors:  Shaoxue Zeng; Ting Zhang; Yingying Chen; Joshua Chu-Tan; Kaiyu Jin; So-Ra Lee; Michelle X Yam; Michele C Madigan; Nilisha Fernando; Adrian Cioanca; Fanfan Zhou; Meidong Zhu; Junjun Zhang; Riccardo Natoli; Xiaohui Fan; Ling Zhu; Mark C Gillies
Journal:  Theranostics       Date:  2022-09-11       Impact factor: 11.600

8.  Identification of histone deacetylase inhibitors with (arylidene)aminoxy scaffold active in uveal melanoma cell lines.

Authors:  Susanna Nencetti; Doretta Cuffaro; Elisa Nuti; Lidia Ciccone; Armando Rossello; Marina Fabbi; Flavio Ballante; Gabriella Ortore; Grazia Carbotti; Francesco Campelli; Irene Banti; Rosaria Gangemi; Garland R Marshall; Elisabetta Orlandini
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

9.  Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma.

Authors:  Carla Barbaraci; Giovanni Giurdanella; Claudia Giovanna Leotta; Anna Longo; Emanuele Amata; Maria Dichiara; Lorella Pasquinucci; Rita Turnaturi; Orazio Prezzavento; Ivana Cacciatore; Elisa Zuccarello; Gabriella Lupo; Giovanni Mario Pitari; Carmelina Daniela Anfuso; Agostino Marrazzo
Journal:  J Med Chem       Date:  2021-09-03       Impact factor: 7.446

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.